Janssen Sciences Ireland Unlimited Company

Janssen Biotech, Inc.

Shannon Mullican

Chichi Huang

Shamina M Rangwala

Xiefan Lin-Schmidt

Jennifer Furman

Serena Nelson

Michael J Hunter

Judith Ann Connor

Anthony A Armstrong

Songmao Zheng

Jose Antonio Chavez

Matthew M Rankin

Xiefan Lin-schmidt

Serena M Nelson

Provided herein are method of using GLP1-GDF15 fusion proteins for reducing food intake, preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others, the fusion protein comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

GDF15 fusion proteins and uses thereof

Growing community of inventors

Philadelphia, PA, United States of America

Shannon Mullican